HC Stocks Broker Alerts- Biocept Inc (BIOC), CytRx Corporation (CYTR)
Shares of Biocept Inc (NASDAQ:BIOC) ended Tuesday session in red amid volatile trading. The shares closed down -0.05 points or -3.52% at $1.37 with 68,126 shares getting traded. Post opening the session at $1.45, the shares hit an intraday low of $1.31 and an intraday high of $1.46 and the price vacillated in this range throughout the day. The company has a market cap of $11.19 million and the numbers of outstanding shares have been calculated to be 8.40 million shares.
Biocept Inc (BIOC) announced a research collaboration with Shilpa Gupta, Ph.D., Assistant Professor in the Hematology Oncology and Transplantation Division of the University of Minnesota to observe the utility of Biocept’s patented Target Selector™ liquid biopsy technology platform using circulating tumor cells (CTCs) to detect the expression of PD-L1 and androgen receptor (AR) in patients diagnosed with bladder and prostate cancers. The study will be conducted at the University of Minnesota Masonic Cancer Center. PD-L1 is expressed in multiple cancer types and its status is required to qualify patients for certain immuno-oncology therapeutics. AR expression is prevalent in patients with advanced prostate cancer.
Shares of CytRx Corporation (NASDAQ:CYTR) ended Tuesday session in red amid volatile trading. The shares closed down -0.020 points or -3.65% at $0.523 with 822,180 shares getting traded. Post opening the session at $0.54, the shares hit an intraday low of $0.52 and an intraday high of $0.55 and the price vacillated in this range throughout the day. The company has a market cap of $51.02 million and the numbers of outstanding shares have been calculated to be 96.94 million shares.
CytRx Corporation (CYTR) operates as a biopharmaceutical research and development company specializing in oncology. The companys product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.